#Potstocks Earnings Roundup: May 29

As we alluded to in an article released Monday morning, there were a number of cannabis focused public companies that released earnings yesterday before and after the bell. To help keep you informed, here’s a run down of what figures some of the more significant players in the market laid down for the first quarter of 2019.

Origin House (CSE: OH)

Origin House started off yesterdays earnings rush, posting their figures in the premarket hours. The California-focused operator posted revenues to the tune of CAD$11.2mm for the first quarter of 2019, with gross margins of $1.7mm. Origin House reported $0.64mm in revenues in the same quarter of 2018, indicating significant top line revenue growth over the course of the last year.

The reported cash position was down $29.95mm to $39.25mm over the three month period, indicating a cash burn of just under $10mm a month.

Overall, Origin House reported a net loss of $17.43mm, up from $4.65mm on a year over year basis. Operating expenses also expanded on a year over year basis, from $4.48mm to that of $18.23mm.

While top line growth historically has been the name of the game in the cannabis sector, it appears that investor sentiment is slowly changing on the topic. After closing Tuesday’s session at $11.49, the equity opened lower at $11.17 on financial results. Ultimately Origin House closed relatively flat on the day at $11.50.

Cresco Labs (CSE: CL)

While Cresco Labs issued a news release after hours related to its earnings, full filings have yet to be issued on Sedar as of the time of writing. What we do know, is that the firm reported revenues of US$21.2mm for the quarter, up 24% from $17.0mm on a quarter over quarter basis. On a pro-forma basis, including the proposed acquisition with Origin House, the company had combined revenues of $33.9mm for the quarter.

Reported gross profits came in at $9.4mm before the impact of biological adjustments, while operating expenses hit $17.7mm.

Cresco Labs posted a net loss of $7.6mm for the first quarter of 2019.

MedMen Enterprises (CSE: MMEN)

MedMen Enterprises was one of the first issuers to report financials after the bell yesterday, posting revenues of US$36.6mm for the period ended March 30, 2019. This was up from the previous quarter, wherein it reported revenues of $29.9mm. On a pro forma basis with all pending acquisitons, including PharmaCann, revenues rose from $49.5mm to $57mm.

There were sparks of positive news embedded within the associated news release, such as a decrease in expenses from $77mm in the previous quarter to $72mm in the current quarter. However, the firm has still failed to break out the recorded $61mm in General and Admin related expenses, which is a significantly higher figure than any industry competitor. It was also announced that CEO Adam Bierman, and President Andrew Modin have signed revised employment contracts, with salaries being reduced to $50,000 a year.

The biggest driver for this phase of the business remains revenue, which continues to increase significantly with new store openings and same store sales growth. Where we are impressively ahead of schedule is in leveraging our scale to create greater operational efficiencies across the organization. Execution keeps improving while corporate SG&A is decreasing.

Adam Bierman, MedMen co-founder and CEO

However, there were more detractors than anything. Cash burn is still immensely high, with the company burning through $56.32mm in just 13 weeks – which equates roughly to $18.8mm leaving the till each month. As of March 30, the company had just $21.9mm in the bank – leaving approximately one month of runway before the company ran out of cash, which identifies the need for the credit facility sourced from Gotham Green Partners. On top of that, intangible assets rose from $96.3mm to $130.7mm, while goodwill rose from $84.8mm to $108.2mm.

MedMen Enterprises reported a net loss of $63.1mm for the quarter, down from $64.6mm for the previous quarter.

Green Growth Brands (CSE: GGB)

Green Growth also reported for the first quarter of calendar 2019 yesterday after the bell, reporting revenues of US$5.6mm, up from $3.1mm. Gross profit however was down on a quarter over quarter basis, with the firm reporting only $79,483 gross profit before fair value adjustments. They reported $1.2mm in gross profits in the previous quarter.

Green Growth Brands Seventh Sense CBD products.
Green Growth Brands Seventh Sense CBD products.

Operating expenses were up by $7mm to $17.1mm, with additional expenditures largely coming from legal and professional fees to the tune of $3.32mm, and stock based compensation with a $1.32mm quarter over quarter increase.

While cash decreased from $31.4mm in the previous quarter to $5.5mm, short term investments rose from $17.3mm to $28.1mm. All told, the company spent $15.17mm throughout the quarter, representing a monthly cash burn rate of $5.06mm.

Green Growth Brands posted a net loss of $15.1mm for the quarter.


FULL DISCLOSURE: Neither The Deep Dive, nor its parent company The CanaCom Group guarantees the accuracy of this information. For informational purposes only. None of the discussed companies are currently clients of Canacom Group nor The Deep Dive.Not a recommendation to buy or sell securities. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver Is in a New Price Regime, and the Market Isn’t Used to It | Keith Neumeyer – First Majestic

Agnico Eagle Just Made a Massive Gold Land Grab

A Copper-Gold Deposit Caught the White House’s Attention | Rob McLeod – Cambria Gold

Recommended

Antimony Resources Expands Footprint as Soil Sampling Lights Up Ground South of Bald Hill

Mercado Drills 256 g/t Silver Over 6.5 Metres In First Drill Hole of Inaugural Program

Related News

Green Growth Brands to Buy Florida Licensed Operator

Green Growth Brands (CSE: GGB) put out a filing through the Canadian Securities Exchange late...

Tuesday, June 4, 2019, 05:00:28 AM

Cresco Labs Receives Regulatory Approval in New York

Cresco Labs (CSE: CL) announced this morning that it had received regulatory approval to proceed...

Thursday, August 8, 2019, 11:34:03 AM

Cresco Labs: Canaccord Drops Price Target To $16

On November 11th, Cresco Labs (CSE: CL) reported its third-quarter financial results. The company reported...

Saturday, November 13, 2021, 01:04:00 PM

Tilray Makes Move Into US Cannabis Market Via Medmen Convertible Notes

It appears that the rumours surrounding Tilray’s (NASDAQ: TLRY) focus on the US cannabis market...

Tuesday, August 17, 2021, 04:30:09 PM

Is the End of the Line Near for MedMen?

It’s long been known by cannabis industry followers that MedMen Enterprises (CSE: MMEN) has a...

Tuesday, June 11, 2019, 07:30:12 AM